Trial Profile
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms POLARIS-01
- Sponsors Shanghai Junshi Biosciences
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 22 Apr 2020 Results published in the Clinical Cancer Research.
- 04 Jun 2019 Results assessing tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy from (NCT02836795 and NCT03013101 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology